Anzeige
Mehr »
Freitag, 04.09.2026 - Börsentäglich über 12.000 News
Bitcoin: Diese 4 Signale entscheiden über Bullenmarkt oder Falle!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0NEDR | ISIN: CA45772U1049 | Ticker-Symbol:
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
INNOVOTECH INC Chart 1 Jahr
5-Tage-Chart
INNOVOTECH INC 5-Tage-Chart
ACCESS Newswire
358 Leser
Artikel bewerten:
(2)

DealFlow Events: Innovotech Inc. Presenting at the 3rd Annual DealFlow Discovery Conference

EDMONTON, AB / ACCESS Newswire / January 26, 2026 / Innovotech Inc. (TSXV:IOT), a leading contract research organization providing proprietary antimicrobial testing and advanced laboratory services for regulated industries, today announced that it will participate in the DealFlow Discovery Conference, taking place January 28-29, 2026.

Craig Milne, CEO of Innovotech Inc. will deliver a company presentation and be available for one-on-one investor meetings throughout the event. Learn more about Innovotech at www.innovotech.ca.

Event Details:

  • 3rd Annual DealFlow Discovery Conference

  • The Borgata Hotel, Casino & Spa

  • Atlantic City, NJ

  • January 28-29, 2026

Investors interested in scheduling a meeting with the Innovotech Inc management team should request an investor pass to attend the conference (no cost to attend).

About Innovotech:

Innovotech Inc. is a Canadian boutique contract research organization specializing in advanced laboratory services and commercializing proprietary technologies. A leader in biofilm science, the company provides expertise in antimicrobial testing, pharmaceutical analysis, and industrial laboratory solutions, supported by innovative methodologies and products including its widely-used MBEC Assay kit for high-throughput antimicrobial and antibiotic testing. Innovotech serves clients across multiple sectors, delivering customized research and testing services designed to meet rigorous regulatory and scientific standards such as those of the U.S. Food and Drug Administration and Health Canada through its ISO-certified and GMP-accredited laboratories. Learn more at https://www.innovotech.ca.

Craig Milne, CEO
Innovotech Inc.
+1-604-239-1819
craig.milne@innovotech.ca

This document may contain forward-looking statements that are predictive in nature and subject to risks and uncertainties that cannot be predicted or quantified; consequently, actual results may differ materially from past results and those expressed or implied by any forward-looking statements. Factors that could cause or contribute to such risks or uncertainties include, but are not limited to: the regulatory environment including the difficulty of predicting regulatory outcomes; changes in the value of the Canadian dollar; the Company's reliance on a small number of customers including government organizations; fluctuations in operating results; government policies or actions; progress and cost of clinical trials; reliance on key strategic relationships; uncertainty related to intellectual property protection and potential costs associated with its defense; the Company's exposure to lawsuits and other matters beyond the control of management. Should known or unknown risks or uncertainties materialize, or should management's assumptions prove inaccurate, actual results could vary materially from those anticipated. The Company undertakes no obligation to publicly make or update any forward- looking statements, except as required by applicable law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Policies or actions; progress and cost of clinical trials; reliance on key strategic relationships; uncertainty related to intellectual property protection and potential costs associated with its defense; the Company's exposure to lawsuits and other matters beyond the control of management. Should known or unknown risks or uncertainties materialize, or should management's assumptions prove inaccurate, actual results could vary materially from those anticipated. The Company undertakes no obligation to publicly make or update any forward- looking statements, except as required by applicable law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

SOURCE: DealFlow Events



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/business-and-professional-services/innovotech-inc.-presenting-at-the-3rd-annual-dealflow-discovery-1130604

© 2026 ACCESS Newswire
KI braucht Strom
Halbleiter, Speicherchips und Rechenzentren haben Anlegern im KI-Boom bereits enorme Gewinne beschert. Doch jetzt zeichnet sich mit der benötigten Energie der nächste große Flaschenhals ab. Neue KI-Rechenzentren benötigen nicht mehr einige Megawatt, sondern zum Teil mehrere Gigawatt Leistung – so viel wie mehrere moderne Kernkraftwerksblöcke.

Damit beginnt ein weltweites Wettrennen um verfügbare Stromkapazitäten. Hyperscaler sichern sich bereits über langfristige Verträge gewaltige Energiemengen, während Stromnetze und Erzeugungskapazitäten mit dem Ausbau kaum Schritt halten können. Zusätzlich verschärfen geopolitische Risiken rund um den Iran-Krieg und die Straße von Hormus die Situation.

Für Energieversorger und ihre Zulieferer könnte damit ein goldenes Zeitalter beginnen. Steigende Nachfrage, langfristige Abnahmeverträge und wachsende Strompreise schaffen ein Umfeld, in dem ausgewählte Unternehmen zum nächsten großen KI-Trade werden könnten.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die besonders stark vom explodierenden Energiehunger der KI profitieren könnten – und bei Anlegern bislang teilweise noch unter dem Radar laufen.

Jetzt den kostenlosen Report sichern – und die nächsten Gewinner des KI-Booms entdecken!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.